Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)

Next Previous
X
Search
Trial Profile

An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases; Systemic scleroderma
  • Focus Adverse reactions
  • Acronyms SENSCIS (TM)-ON; SENSCIS(R) -ON
  • Sponsors Boehringer Ingelheim; Unilfarma

    • Most Recent Events

    • 15 Nov 2023 Results of pooled SENSCIS and SENSCIS -ON trials, presented at the ACR Convergence 2023 .
    • 09 Jun 2023 Pooled data from SENSCIS (n=277) and SENSCIS -ON (n=225) studies, published in the Rheumatology.
    • 03 Jun 2023 Results to assess adverse events over 148 weeks, presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top